Spirit shares took a nosedive on news of a possible bankruptcy filing. The budget carrier and its bondholders have discussed ...

Eli Lilly & Co. closed $85.37 below its 52-week high ($972.53), which the company reached on August 22nd.

The FDA confirmed Thursday that Eli Lilly has increased production of its blockbuster weight-loss drug Zepbound and type 2 ...

The FDA determined the shortage of Eli Lilly And Co’s (NYSE:LLY) tirzepatide injection, a glucagon-like peptide 1 (GLP-1) ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 569.58% and ...

Newly released data shows that the U.S. may have reached peak obesity in 2020 — and the timing unsurprisingly coincides with ...

Texas is suing insulin manufacturers and PBMs, including Eli Lilly and CVS Pharmacy, alleging a scheme to hike insulin prices ...

GLP-1 weight-loss drugs Mounjaro and Zepbound have been removed from the Food and Drug Administration's (FDA) shortage list. ...

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include ...

Americans who turned to telehealth companies and compounding pharmacies for cheap versions of Eli Lilly & Co.’s weight-loss ...

Scaling GLP-1 manufacturing capacity remains a key priority for the pharma industry, to help supply catch up with the ...

The roadmap suggests those with the greatest clinical need will get priority access, according to the NHS national medical ...